000289904 001__ 289904
000289904 005__ 20250824022517.0
000289904 0247_ $$2doi$$a10.1016/j.maturitas.2024.107998
000289904 0247_ $$2pmid$$apmid:38678818
000289904 0247_ $$2ISSN$$a0378-5122
000289904 0247_ $$2ISSN$$a1873-4111
000289904 0247_ $$2altmetric$$aaltmetric:163130837
000289904 037__ $$aDKFZ-2024-00896
000289904 041__ $$aEnglish
000289904 082__ $$a150
000289904 1001_ $$0P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aChen, Li-Ju$$b0$$eFirst author$$udkfz
000289904 245__ $$aLongitudinal associations of polypharmacy and frailty with major cardiovascular events and mortality among more than half a million middle-aged participants of the UK Biobank.
000289904 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2024
000289904 3367_ $$2DRIVER$$aarticle
000289904 3367_ $$2DataCite$$aOutput Types/Journal article
000289904 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1714395348_28367
000289904 3367_ $$2BibTeX$$aARTICLE
000289904 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289904 3367_ $$00$$2EndNote$$aJournal Article
000289904 500__ $$a#EA:C070#LA:C070#
000289904 520__ $$aStudies of the associations of polypharmacy and frailty with adverse health outcomes in middle-aged adults are limited. Furthermore, a potentially stronger association of polypharmacy with adverse health outcomes in frail than in non-frail adults is of interest.To evaluate associations of frailty (assessed using a frailty index) and polypharmacy (defined as taking five or more drugs) with major cardiovascular events, cancer incidence, all-cause, cardiovascular disease-specific, and cancer-specific mortality.Cox proportional hazards regression models were used to analyze 501,548 participants of the UK Biobank cohort study aged 40-69 years who were followed up for an average of 12 years.The prevalence of pre-frailty and frailty were 43.2 % and 2.3 %, respectively, and that of polypharmacy was 18.3 %. Although strongly associated with each other, frailty and polypharmacy were independently, statistically significantly associated with major cardiovascular events, cardiovascular disease-specific, and all-cause mortality. In addition, the hazard ratios of polypharmacy were stronger among (pre-)frail than non-frail study participants. No profound associations with cancer incidence and cancer mortality were observed. No sex and age differences were observed.This large cohort study showed that polypharmacy and frailty are independent risk factors for major cardiovascular events, cardiovascular disease-specific and all-cause mortality in both middle-aged (40-64 years) and older people (≥ 65 years). In addition, the hazard ratios of polypharmacy were stronger among (pre-)frail than non-frail study participants. This underlines the need to avoid polypharmacy as far as possible not only in older but also in middle-aged subjects (40-64 years), especially if they are pre-frail or frail.
000289904 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000289904 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289904 650_7 $$2Other$$aCardiovascular disease mortality
000289904 650_7 $$2Other$$aFrailty
000289904 650_7 $$2Other$$aMACE
000289904 650_7 $$2Other$$aMortality
000289904 650_7 $$2Other$$aPolypharmacy
000289904 7001_ $$0P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aSha, Sha$$b1$$udkfz
000289904 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$udkfz
000289904 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b3$$eLast author$$udkfz
000289904 773__ $$0PERI:(DE-600)2008054-2$$a10.1016/j.maturitas.2024.107998$$gVol. 185, p. 107998 -$$p107998$$tMaturitas$$v185$$x0378-5122$$y2024
000289904 8564_ $$uhttps://inrepo02.dkfz.de/record/289904/files/1-s2.0-S0378512224000938-main.pdf
000289904 8564_ $$uhttps://inrepo02.dkfz.de/record/289904/files/1-s2.0-S0378512224000938-main.pdf?subformat=pdfa$$xpdfa
000289904 909CO $$ooai:inrepo02.dkfz.de:289904$$pVDB
000289904 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289904 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289904 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289904 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289904 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000289904 9141_ $$y2024
000289904 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-26$$wger
000289904 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMATURITAS : 2022$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-26
000289904 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000289904 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000289904 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000289904 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000289904 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000289904 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000289904 980__ $$ajournal
000289904 980__ $$aVDB
000289904 980__ $$aI:(DE-He78)C070-20160331
000289904 980__ $$aI:(DE-He78)C120-20160331
000289904 980__ $$aI:(DE-He78)HD01-20160331
000289904 980__ $$aUNRESTRICTED